Source: http://www.google.com/patents/US7772220?dq=U.S.+Patent+
Timestamp: 2017-08-24 11:56:59
Document Index: 741201459

Matched Legal Cases: ['Application No. 200580037307', 'Application No. 200480044467', 'Application No. 200580028815', 'Application No. 200580034884', 'Application No. 05', 'Application No. 04', 'Application No. 05', 'Application No. 05', 'Application No. 05', 'art 2', 'Application No. 181434', 'Application No. 2000']

Patent US7772220 - Methods and compositions for reducing toxicity of a pharmaceutical compound - Google Patents
The present disclosure is related to clear aqueous solutions of one or more bile acids and either an aqueous soluble starch conversion product or a non-starch polysaccharide. Solutions of the disclosure may be administered to a subject in conjunction with a pharmaceutical compound having one or more...http://www.google.com/patents/US7772220?utm_source=gb-gplus-sharePatent US7772220 - Methods and compositions for reducing toxicity of a pharmaceutical compound
Publication number US7772220 B2
Application number US 11/251,137
Also published as CN101378769A, EP1940428A1, EP1940428A4, US20060089331, WO2007044062A1, WO2007044062A8
Publication number 11251137, 251137, US 7772220 B2, US 7772220B2, US-B2-7772220, US7772220 B2, US7772220B2
Patent Citations (88), Non-Patent Citations (266), Referenced by (4), Classifications (21), Legal Events (3)
US 7772220 B2
US6309663 * Aug 17, 1999 Oct 30, 2001 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6635628 * Jun 17, 2002 Oct 21, 2003 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
US7034006 Jan 10, 2001 Apr 25, 2006 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US20020031558 * Feb 5, 2001 Mar 14, 2002 Yoo Seo Hong Preparation of aqueous clear solution dosage forms with bile acids
AU3735899A Title not available
JP6024991B2 Title not available
2 "Clean, Beautiful, Healthy Life ", LG Household & Health Care, http://www.lgcare.com/english/aboutus/06.html, pp. 3, Feb. 27, 2006.
3 "Colfosceril Palmitate", Tiscali, http://www.tiscali.co.uk/lifestyle/healthfitness/health-advice/netdoctor/archive/100003422.html , pp. 2, 1998-2004.
4 "Colfosceril Palmitate", Tiscali, http://www.tiscali.co.uk/lifestyle/healthfitness/health—advice/netdoctor/archive/100003422.html , pp. 2, 1998-2004.
6 "Dacarbazine", NCI Terminology Browser, http://nciterms.nci.nih.gov/NCIBrowser/PrintableReport.jsp?dictionary=NCI-Thesaurus&code=C411 , pp .3, Nov. 2005.
7 "Dacarbazine", NCI Terminology Browser, http://nciterms.nci.nih.gov/NCIBrowser/PrintableReport.jsp?dictionary=NCI—Thesaurus&code=C411 , pp .3, Nov. 2005.
8 "Denavir", PDRhealth, http://www.pdrhealth.com/drug info/rxdrugprofiles/drugs/den1123.shtml , pp. 2, Feb. 8, 2006.
9 "Diethyldithiocarbamate", http://nciterms.nci.nih.gov/NCIBrowser/ConceptRecords.jsp?, pp. 2, Feb. 6, 2006.
10 "Drug Information: Bronchodilators, Andrenergic (Inhalation)", Medline Plus, http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202095.html , pp. 12, Jun. 25, 2003.
11 "Drug Information: Celecoxib", Medline Plus, http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a699022.html , pp. 4, Jan. 1, 2006.
12 "Drug Information: Dacarbazine", Medline Plus, http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682750.html , pp. 2, Apr. 1, 2003.
13 "Drug Information: Dyphylline (Systemic)", Medline Plus, http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202752.html , pp. 4, Jun. 14, 1999.
14 "Drug Information: Hydralazine", Medline Plus, http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682246.html , pp. 3, Apr. 1, 2003.
15 "Drug Information: Isoxsuprine (Systemic)", Medline Plus, http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202310.html , pp. 4, Jul. 15, 1994.
16 "Drug Information: Nylidrin (Systemic)", Medline Plus, http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202416.html , pp. 3, May 14, 1993.
17 "Maltrin Maltodextrins & Corn Syrup Solids Chemical and Physical Properties" GPC Technical Bulletin, TB31-021296, Grain Processing Corp. (Brochure + 4 pages), 1999.
18 "Pharmaceutical Necessities", Remington: The Science and Practice of Pharmacy, Mack Printing Co., Easton, Pennsylvania (1995) pp. 1409-1410.
19 "Powered by Dorland's Illustrated Medical Dictionary: E", MerckSource, http://www.mercksource.com/pp/us/cns/cns-hl-dorlands.jspzQzpgzEzzSzppdocszSzuszSzcommonzSzdorlandszSzdorlandzSzdmd-e-17zPzhtm, pp. 3, Feb. 27, 2006.
20 "Powered by Dorland's Illustrated Medical Dictionary: E", MerckSource, http://www.mercksource.com/pp/us/cns/cns—hl—dorlands.jspzQzpgzEzzSzppdocszSzuszSzcommonzSzdorlandszSzdorlandzSzdmd—e—17zPzhtm, pp. 3, Feb. 27, 2006.
21 "Proventil", PDR Health, http://www.pdrhealth.com/drug-info/rxdrugprofiles/drugs/pro1360.shtml, pp. 5, Feb. 8, 2006.
22 "Proventil", PDR Health, http://www.pdrhealth.com/drug—info/rxdrugprofiles/drugs/pro1360.shtml, pp. 5, Feb. 8, 2006.
23 "Saccharide Composition Typical Carbohydrate Profiles" GPC Technical Bulletin TB30-021296, Grain Processing Corp. (1 page), 1999.
24 "Selenium", PDR Health, http://www.pdrhealth.com/drug-info/nmdrugprofiles/nutsupdrugs/sel-0232.shtml, pp. 8, Feb. 27, 2006.
25 "Selenium", PDR Health, http://www.pdrhealth.com/drug—info/nmdrugprofiles/nutsupdrugs/sel—0232.shtml, pp. 8, Feb. 27, 2006.
26 "Zovirax", PDRhealth, http://www.pdrhealth.com/drug info/rxdrupprofiles/drugs/zov1505.shtml , pp. 4, Feb. 8, 2006.
27 * 2006 Chemical Abstracts catalog, published 2006 by Chemical Abstracts Service, p. 52.
28 27th Annual Meeting of the Korean Neurological Association; "Oral Presentation"; Journal of the Korean Neurological Association; vol. 26, Suppl. 2; pp. 3, 2008.
29 A. Benjamin Suttle and Kim L. R. Brouwer, "Regional Gastronintestinal Absorption of Ranitidine in the Rat", Pharmaceutical Research, (1995) Vol. 12, No. 9 pp. 1311-1315. 1995.
30 A. Björkland and T.H. Totterman, "Is Primary Biliary Cirrhosis an Autoimmune Disease?", Scand J. Gastroenteral (1994) 29 Suppl. 204:32-9.
31 A. Stiehl, "Ursodeoxycholic Acid Therapy in Treatment of Primary Sclerosing Cholangitis", Scand J Gastroenterol (1994) 29 Suppl. 204:59-61.
32 A.C. Peltier et al.; "Recent Advances in Drug-Induced Neuropathies"; Current Opinion in Neurology, vol. 15; pp. 633-638, 2002.
33 A.D. McNaught, "Nomenclature of Carbohydrates", Pure and Applied Chemistry, vol. 68, pp. 1919-2008, 1996.
34 A.F. Hofmann, "Pharmacology of Ursodeoxycholic Acid, an Enterohepatic Drug", Scand J. Gastroenteral (1994) 29 Suppl. 204:1-15.
35 Aigner A and Bauer A, "Bile acids, Long known active substances with a future", Med Monatsschr Pharm (1988) (11): 369-75.
36 Angelin et al., "Effects of Ursodeoxycholic Acid on Plasma Lipids", Scand J. Gastroenterol. (1994) 29 Suppl 204:24-26.
37 Armstrong et al., "The Hydrophobic-Hydrophilic Balance of Bile Salts. Inverse Correlation between Reverse-Phase High Performance Liquid Chromatographic Mobilities and Micellar Cholesterol-Solubilizing Capacities", J. Lipid Research, (1982) vol. 23 pp. 70-80.
38 * Barbarotto et al., "Differential Effects of Chemotherapeutic Drugs Versus the MDM-2 Antagonist Nutlin-3 on Cell Cycle Progression and Induction of Apoptosis in SKW6.4 Lymphoblastoid B-Cells" Journal of Cellular Biochemistry (2008) vol. 140, pp. 595-605.
39 Beuers et al., "Ursodeoxycholic Acid for Treatment of Primary Sclerosing Cholangitis: A Placebo-controlled Trial", Hepatology. (1992) vol. 16, No. 3, pp. 707-714.
40 Binek et al., "Bedeutung von Ursodeoxycholsäure bei der Eradikation von Helicobacter pyloni", Schweitz Med Wochenschr (1996) 126 (Suppl. 79): 44S-46S.
41 Boberg et al., "Etiology and Pathogenesis in Primary Sclerosing Cholangitis", Scand J. Gastroenterol (1994) 29 Suppl. 204:47-58.
42 Bode et al., "Polymorphism in Helicobacter pylori—a key function in recurrence of infection", Medizinische Klinik, (1992) 87(4):179-84.
43 Brazilian Office Action for Patent Application PI 9912395-9, 6 pages, Dec. 5, 2008
44 Buckley et al., "Controlled Release Drugs in Overdose Clinical Consideration", Drug Safety (1996) vol. 12, No. 1 pp. 73-84.
45 C.A. Ventura et al.; "Improvement of Water Solubility and Dissolution Rate of Ursodeoxycholic Acid and Chenodeoxycholic Acid by Complexation With Natural and Modified beta-Cyclodextrins"; International Journal of Pharmaceutics; vol. 149; pp. 1-13, 1997.
46 C.A. Ventura et al.; "Improvement of Water Solubility and Dissolution Rate of Ursodeoxycholic Acid and Chenodeoxycholic Acid by Complexation With Natural and Modified β-Cyclodextrins"; International Journal of Pharmaceutics; vol. 149; pp. 1-13, 1997.
47 C.D. Keene et al.; "A Bile Acid Protects Against Motor and Cognitive Deficits and Reduces Striatal Degeneration in the 3-Nitropropionic Acid Model of Huntington's Disease"; Experimental Neurology, vol. 171; pp. 351-360, 2001.
48 C.J. Newton et al.; "Fluvastin Induces Apoptosis of Vascular Endothelial Cells: Blockade by Glucocorticoids"; Cardiovascular Surgery, vol. 11, No. 1; pp. 52-60, 2003.
49 C.M.P. Rodrigues et al.; "Bilirubin and Amyloid-β Peptide Induce Cytochrome c Release Through Mitochondrial Membrane Permeabilization"; Molecular Medicine, vol. 6, No. 11; pp. 936-946, 2000.
50 C.M.P. Rodrigues et al.; "Neuroprotection by a Bile Acid in an Acute Stroke Model in the Rat"; Journal of Cerebral Blood Flow & Metabolism, vol. 22; pp. 463-471, 2002.
51 C.M.P. Rodrigues et al.; "The Therapeutic Effects of Ursodeoxycholic Acid as an Anti-Apoptotic Agent"; Expert Opin. Investig. Drugs, vol. 10, No. 7; pp. 1243-1253, 2001.
52 Cannon et al. "Reduction of pain on intravenous infusion with bile salt formulations for a macrolide antibiotic" International Journal of Pharmaceutics, vol. 114, No. 1 (pp. 65-74), Jul. 13, 1994.
53 Carey et al., "Micelle Formation by Bile Salts", Arch Intern Med, (1972) vol. 130, pp. 506-527.
54 Carey, MD et al. "Micelle Formation by Bile Salts Physical-Chemical and Thermodynamic Considerations" Arch. Intern. Med., vol. 130 (pp. 506-527), Oct. 1972.
55 Cecilia M.P. Rodrigues et al., "Ursodeoxycholic Acid May Inhibit Deoxycholic Acid-Induced Apoptosis by Modulating Mitochondrial Transmembrane Potential and Reactive Oxygen Species Production", Molecular Medicine, vol. 4, pp. 165-178, 1998.
56 Chad Silverberg; "Atorvastatin-Induced Polyneuropathy"; www.PubMed.com ; pp. 5, Nov. 4, 2003.
57 Chazouilleres et al., "Ursodeoycholic Acid for Primary Sclerosing Cholangitis", J. Hepatology, (1990) vol. 11 pp. 120-123.
58 * Chemical Abstracts Registry entry 191595-91-2, "Bamet R2" copyright 2007 American Chemical Society.
59 * Chemical Abstracts Registry entry 265093-50-3, "Bamet UD2" copyright 2007 American Chemical Society.
60 * Chemical Abstracts Registry entry 64480-66-6 "Glycoursodeoxycholic acid" copyright 2007 American Chemical Societ.
61 Chinese Office Action for Patent Application 01804549.9, 6 pages, Oct. 30, 2008.
62 Chinese Office Action; Application No. 200580037307.8; pp. 6, May 15, 2009.
63 Chu et al. "Human neural stem cells improve sensorimotor deficits in the adult rat brain with experimental focal ischemia" Brain Research 1016 (pp. 145-153), 2004.
64 Cirillo N.W. and F.R. Zwas., "Ursodeoxycholic Acid in the Treatment of Chronic Liver Disease", Am J Gastroenterol (1994) vol. 89, No. 9 pp. 1447-1452.
65 CN Office Action; Application No. 200480044467.0; pp. 7, Mar. 27, 2009.
66 CN Office Action; Application No. 200580028815.X; pp. 10, Mar. 13, 2009.
67 CN Office Action; Application No. 200580034884.1; pp. 6, Mar. 27, 2009.
68 * Cole et al., "Efficacy and Safet of Perhexiline Maleate in Refractory Angina" Circulation (1990) vol. 81 pp. 1260-1270.
69 Colombo et al., "Effects of Ursodeoxycholic Acid Therapy for Liver Disease Associated with Cystic Fibrosis", J. of Pediatrics, (1990) vol. 117, No. 3 pp. 482-489.
70 Colombo et al., "Ursodeoxycholic Acid Therapy in Cystic Fibrosis-associated Liver Disease: A Dose-response Study", Hepatology, (1992) vol. 16, No. 4 pp. 924-930.
71 Communication pursuant to Article 94(3) EPC; Application No. 05 813 305.9-1216; pp. 7, Mar. 7, 2008.
72 * Coudron et al., "In-vitro evaluation of nitrofurantoin as an alternative agent for metronidazole in combination antimicrobial therapy against Helicobacter pylori" Journal fo Antimicrobial Chemotherapy (1998) vol. 42 pp. 657-660.
73 Crosignani, et al., "Clinical Pharamcokinetics of Therapeutic Bile Acids", Clin. Pharmacokinet, (1996) vol. 30, No. 5 pp. 333-358.
74 D. Chapman-Shimshoni et al.; "Simvastatin Induces Apoptosis of B-CLL cells by Activation of Mitochondrial Caspase 9"; Experimental Hematology, vol. 31; pp. 779-783, 2003.
75 D. Gaist et al.; "Statins and Risk of Polyneuropathy"; Neurology, vol. 58; pp. 1333-1337, May 2002.
76 D. Lapenna et al.; "Antioxidant Properties of Ursodeoxycholic Acid"; Biochemical Pharmacology, vol. 64; pp. 1661-1667, 2002.
77 D.L. Nelson, "Carbohydrates and Glycobiology", Lehninger Principles of Biochemistry,Fourth Edition, pp. 238-271, 2005.
78 D.S. Alberts et al., "Phase III Trial of Ursodeoxycholic Acid to Prevent Colorectal Adenoma Recurrence", Journal of National Cancer Institute, vol. 97, No. 11, pp. 846-853, Jun. 1, 2005.
79 Database WPI Section Ch, Week 198824 Derwent Publications Ltd., London, GB, AN-1988-165730 XP002337363 & JP 63104925 A, 1988.
80 Database WPI Section Ch, Week 198846 Derwent Publications Ltd., London, GB, AN-1988-327783 XP002337364 & JP 63243031 A, 1988.
81 De Caprio et al., "Bile Acid and sterol solubilization in 2-hydroxypropyl-β-cyclodextrin", Journal of Lipid Research, (1992) vol. 33, pp. 441-443.
82 Deborah F. Gelinas; "Riluzole"; ALS and Other Motor Neuron Disorders,(Suppl 4); pp. 3-4, 2000.
83 Dioguardi et al., "The role of oral branched-chain amino acids (BCAAs) in the elevation of plasma ammonia (pNH3)", Chapter 68, in Advances in Ammonia Metabolism and Hepatic Encephalopathy, Soeters et al., eds., (1988) Elsevier Science Publishers B.V., pp. 527-533. 1988.
84 Dominguez et al. "Low in Vivo Toxicity of a Novel Cisplatin-Ursodeoxycholic Derivative (Barnet-UD2) with Enhanced Cytostatic Activity versus Liver Tumors" Journal of Pharmacology and Experimental Therapeutics, vol. 297, No. 3 (pp. 1106-1112), Jan. 16, 2001.
85 Dressman et al., "Gastrointestinal Parameters that Influence Oral Medications", J. of Pharmaceutical Sciences, (1993) vol. 82, No. 9 pp. 857-872.
86 Drug Name: Tauroursodeoxycholic Acid (TUDCA), TUDCA-Various/UDCA (Ursodiol-Actigall, Watson Pharmacceuticals, Novartis, Generics), 7 pages, 2004.
87 * Dudley et al., "Attenuated p53 activation in tumor-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine" British Journal of Cancer (2008) vol. 99, pp. 118-125.
88 E. Diguet et al.; "Effects of Riluzole on Combined MPTP + 3-Nitropropionic Acid-Induced Mild to Moderate Striatonigral Degeneration in Mice"; Journal of Neural Transmission; pp. 19, 2004.
89 E. Nagy et al., "Imuthiol Inhibits the Etoposide-Induced Apoptosis in HL-60 Cells" Immunology Letters vol. 64, pp. 1-4, 1998.
90 EMEA/CHMP/EWP Workshop; "Slowing the Progression of Neurodegenerative Diseases: Medicinal Productions (MP) Clinical Development"; European Medicines Agency, Pre-authorisation Evaluation of Medicines for Human Use; http://www.emea.europa.eu; pp. 15, Oct. 2, 2006.
91 European Office Action for Application No. 04 812 094.3, 8, Applicant: Seo Hong Yoo, 8 pages, Dec. 17, 2007.
92 European Office Action for Application No. 05 820 886.9, 3 pages, Nov. 14, 2008.
93 European Office Action; Application No. 05 792 858.2-2123; pp. 4, May 20, 2009.
94 European Office Action; Application No. 05 813 305.9-1216; pp. 16, Jan. 19, 2010.
95 F. Lanzarotto et al., "Effect of Long-Term Simvastatin Administration as an Adjunct to Ursodeoxycholic Acid: Evidence for a Synergistic Effect on Biliary Bile Acid Composition but Not on Serum Lipids in Humans", GUT, (1999) vol. 4 pp. 552-556.
96 F. S. Giorgi et al., "The role of norepinephrine in epilepsy: from the bench to the bedside" Neurosci. Behavioral. Rev.. vol. 28, pp. 507-524, 2004.
97 Fiaccadori et al., "The effect of dietary supplementation with branch-chain amino acids (BCAAs) vs. casein in patients with chronic recurrent portal systemic encephalopathy: a controlled trial", pp. 489-497. (1988) Elsevier Science Publishers B.V. Advances in ammonia metabolism and hepatic encephalopathy.
98 * Fox et al., "Short Analytical Review: Mechanism of Action for Leflunomide in Rheumatoid Arthritis" Clinical Immunology (1999) vol. 93 No. 3, pp. 198-208.
99 Fried et al., "Ursodeoxycholic Acid Treatment of Refractory Chronic Graft-versus-Host Disease of the Liver", Annals of Internal Medicine, (1992) 116:624-629.
100 Frömming, "Cyclodextrin Derivatives", Cyclodextrins in Pharmacy, Chapter 2, pp. 19-32, 1994.
101 Frömming, "Cyclodextrins", Cyclodextrins in Pharmacy, Chapter 1, pp. 1-18, 1994.
102 G. Buck, "Campylobacter pylori and Gastrroduodenal Disease". Clinical Microbiology Reviews, (1990) vol. 3, No. 1 pp. 1-12.
103 G. H. P. Te Wierik et al., "Preparation, Characterization and Pharmaceutical Application of Linear Dextrins: IV. Drug Release from Capsules and Tablets Containing Amylodextrin", International J. of Pharmaceutics, (1993) vol. 98 pp. 219-224.
104 G.D. Ghadge et al.; "Mutant Superoxide Dismutase-1-Linked Familial Amyotrophic Lateral Sclerosis: Molecular Mechanisms of Neuronal Death and Protection"; The Journal of Neuroscience, vol. 17, No. 22; pp. 8756-8766, Nov. 15, 1997.
105 Gerhard Schmid, "Preperation and Industrial Production of Cyclodextrins", Comprehensive Supramolecular Chemistry, vol. 3, pp. 41-56, 1996.
106 Gerrit H. P. Te Wierik et al., "Preparation, Characterization, and Pharmaceutical Application of Linear Dextrins, I. Preparation and Characterization of Amylodextrin, Metastable Amylodextrins, and Metastable Amylose", Pharmaceutical Research, (1993) vol. 10, No. 9 pp. 1274-1279.
107 Gerritt H. P. Te Wierik et al., "Preparation, Characterization, and Pharmaceutical Application of Linear Dextrins. II. Complexation and Dispersion of Drugs with Amylodextrin by Freeze-Drying and Kneading", Pharmaceutical Research, vol. 10, No. 9 pp. 1280-1284.
108 Golub et al., "Physiologic Considerations in Drug Absorption from the Gastrointestinal Tract", J. Allergy Clin. Immunol., (1986) vol. 78, No. 4, Part 2 pp. 689-694.
109 Gordon et al., "Nasal Absorption of Insulin: Enhancement by Hydrophobic Bile Salts", Proc. Natl. Acad. Sci., (1985) vol. 82 pp. 7419-7423.
110 * Govindarajan et al., "Irinotecan and thalidomide in metastatic colorectal cancer" Oncology (2000) vol. 14 No. 12 suppl 13, abstract.
111 * Graham et al., "Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance" Alimentary Pharmacology and Therapeutics (2001) vol. 15 pp. 513-518.
112 H.P.R. Bootsma et al.; "beta-Cyclodextrin as an Excipient in Solid Oral Dosage Forms: in Vitro and in Vivo Evaluation of Spray-Dried Diazepam-beta-Cyclodextrin Products"; Inernation Journal of Pharmaceutics, vol. 51; pp. 213-223, 1989.
113 H.P.R. Bootsma et al.; "β-Cyclodextrin as an Excipient in Solid Oral Dosage Forms: in Vitro and in Vivo Evaluation of Spray-Dried Diazepam-β-Cyclodextrin Products"; Inernation Journal of Pharmaceutics, vol. 51; pp. 213-223, 1989.
114 H.R. Horton, "Carbohydrates", Principles of Biochemistry, Second edition, pp. 228-234, 1996.
115 Hammad et al. "Increasing Drug Solubility by Means of Bile Salt-Phosphatidylcholine-Based Mixed Micelles" European J. of Pharmaceutics and Biopharmaceutics, vol. 46 (pp. 361-367), 1998.
116 Hammad et al. "Solubility and Stability of Tetrazepam in Mixed Micelles" European J. of Pharmaceutical Sciences, vol. 7, (pp. 49-55) 1998.
117 Han et al., "The Interaction of pH, Bile and Helicobacter pylori May Explain Duofenial Ulcer", American Journal of Gastroenterology (1996) vol. 91, No. 6, pp. 1135-1137.
118 * Hempfling et al., "Systematic review: ursodeoxycholic acid-adverse effects and drug interactions" Alimentary Pharmacology and Therapeutics (2003) vol. 18 pp. 963-972.
119 * Hempfling et al., "Systematic review: ursodeoxycholic acid—adverse effects and drug interactions" Alimentary Pharmacology and Therapeutics (2003) vol. 18 pp. 963-972.
120 Higginbottom et al., International Journal of Pharmaceutics, vol. 109, pp. 173-180, 1994.
121 Hirai et al. "Mechanisms for the Enhancement of the Nasal Absorption of Insulin by Surfactants" International J. of Pharmaceutics, vol. 9 (pp. 173-184), 1981.
122 Hirai et al., "Effect of Surfactants on the Nasal Absorption of Insulin in Rats", International J. of Pharmaceutics, (1981) vol. 9 pp. 165-172. 1981.
123 Hirai et al., "Mechanisms for the Enhancement of the Nasal Absorption of Insulin by Surfactants", International J. Phamaceutics, (1981) vol. 9 pp. 173-184.
124 Hofmann et al.; "Bile Acid Solubility and Preperation in Vitro and in Vivo: The Role of Conjugation, pH, and Ca2+ Ions"; Journal of Lipid Research, vol. 33; pp. 617-626, 1992.
125 Hollander et al. "Intestinal Absorption of Aspirin Influence of pH, Taurocholate, Ascorbate and Ethanol" J. of Lab. Clin. Med., vol. 98, No. 4 (pp. 591-595), Oct. 1980.
126 Hollander et al., "Intestinal Absorption of Aspirin, Influence of pH, Taurocholate, Ascorbate and Ethanol", J. Lab. Clin. Med., (1981) vol. 98, No. 4 pp. 591-595.
127 * Howard et al., Suramin Increases p53 Protein Levels but Does Not Activate the p53-dependent G1 Checkpoint Clinical Cancer Research (1996) vol. 2 pp. 269-276.
128 Hubner et al., "Enhancement of Monocyte Antimycobacterial Activity by Diethyldithiocarbamate (DTC)" Int. J. Immunopharmac, vol. 13, pp. 1067-1072, 1991.
129 I. Björkhem, "Inborn Errors of Metabolism with Consequences for Bile Acid Biosynthesis: A Minireview", Scand J. Gastroenteral (1994) 29 Suppl. 204:68-72.
130 Igimi et al. "ph-Solubility Relations of Chenodeoxycholic and Ursodeoxycholic Acids: Physical-Chemical Basis for Dissimilar Solution and Membrane Phenomena" J. of Lipid Research, vol. 21 (pp. 72-90), 1980.
131 Igimi et al., "pH-Solubility Relations of Chenodeoxycholic and Ursodeoxycholic Acids: Physical-Chemical Basis for Dissimilar Solution and Membrane Phenomena", J. Lipid Research, (1980) vol. 21 pp. 72-90.
132 Ikeda et al., "Antioxidant Nutrients and Hypoxia/Ischemia Brain Injury in Rodents", Toxicology vol. 189, pp. 55-61, 2003.
133 International Preliminary Report on Patentability and Written Opinion for International Application No. PCT/US2004/039507 (21 pages), Jun. 7, 2007.
134 International Preliminary Report on Patentability and Written Opinion for International Application No. PCT/US2005/030679 (9 pages), Mar. 6, 2007.
135 International Preliminary Report on Patentability for International Application No. PCT/US2005/037211 (10 pages), Apr. 26, 2007.
136 International Preliminary Report on Patentability for International Application No. PCT/US2005/039089 (9 pages), May 10, 2007.
137 International Preliminary Report on Patentability; PCT/US2006/036325; pp. 8, Mar. 26, 2009.
138 International Search Report and Written Opinion for International Application No. PCT/US2005/037211 (16 pages), Feb. 13, 2007.
139 International Search Report and Written Opinion for International Application No. PCT/US2006/036325 (13 pages), Jun. 4, 2007.
140 International Search Report and Written Opinion; PCT/US2005/039089; pp. 15, Mailed: May 24, 2006.
141 Invernizzi et al. "Differences in the Metabolism and Disposition of Ursodeoxycholic Acid and of its Taurine-Conjugated Species in Patients with Primary Biliary Cirrhosis" Hepatology, vol. 29, No. 2 (pp. 320-327), Feb. 1999.
142 Isreal Office Action; Application No. 181434; pp. 1, Sep. 7, 2009.
144 * Itoh et al., "Antibacterial action of bile acids against Helicobacter pylori and changes in its ultrastructural morphology: effect of unconjugated dihydroxy bile acid" Journal of Gastroenterology (1999) vol. 34 pp. 571-576.
145 Itoh et al.; "Antibacterial action of bile acids against Helicobacteria pylori and changes inits ultrastructural morphology: effect of unconjugated dihydroxy bile acid"; J. Gastroenterol, vol. 34, pp. 571-576, 1999.
146 J.F. Dasta et al.; "Comparison of Visual and Turbidimetric Methods for Determining ShortTerm Compatibility of Intravenous Critical-Care Drugs"; American Journal of Hospital Pharmacy; vol. 45; pp. 2361-2366, Nov. 1988.
147 Japanese Office Action (w/translation); Application No. 2000-560868; pp. 10, Oct. 9, 2009.
148 * Jones et al., "The role of dexamethasone in the modification of misonidazole pharmacokinetics" British Journal of Cancer (1983) vol. 48 No. 4, pp. 553-557.
149 Jorgensen et al., "Characterisation of patients with a complete biochemical response to ursodeoxycholic acid", GUT (1995) 36:935-938, .
150 K. Bodin et al., "Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4" J. Biol. Chem. vol. 276, pp. 38685-38689, Oct. 19, 2001.
151 K. Einarsson, "Effect of Urodeoxycholic Acid on Hepatic Cholesterol Metabolism", Scand J. Gastroenteral (1994) 29 Suppl. 204:19-23.
152 K. Müller, "Structural Aspects of Bile Salt-Lecithin Mixed Micelles", Hepatology, (1984) vol. 4, No. 5 pp. 134S-137S.
153 K.G. Rajesh et al., "Hydrophilic Bile Salt Ursodeoxycholic Acid Protects Myocardium Against Reperfusion Injury in a P13K/Akt Dependent Pathway", Journal of Molecular and Cellular Cardiology, vol. 39, pp. 766-776, 2005.
154 Kathleen Parfitt: "Martindale: The Complete drug reference, 32nd edition", Pharmaceutical Press, London, UK, pp. 513-515 (Cisplatin), Jan. 1, 1999.
155 Kathleen Parfitt: "Martindale: The Complete drug reference, 32nd edition", Pharmaceutical Press, London, UK, pp. 556-558 (Paclitaxel), Jan. 1, 1999.
156 Kathleen Parfitt: "Martindale: The Complete drug reference, 32nd edition", Pharmaceutical Press, London, UK, pp. 593 (Sumarin), Jan. 1, 1999.
157 Kathleen Parfitt: "Martindale: The Complete drug reference, 32nd edition", Pharmaceutical Press, London, UK, pp. 607-609 (Didanosine), Jan. 1, 1999.
158 Kathleen Parfitt: "Martindale: The Complete drug reference, 32nd edition", Pharmaceutical Press, London, UK, pp. 629-630 (Zalcitabine), Jan. 1, 1999.
159 Keith D. Lindor, M.D., "Ursodiol for Primary Sclerosing Cholangitis", The New England Journal of Medicine, (1997) vol. 336, No. 10., pp. 691-695.
160 Kimura et al., "A 1-h Topical Therapy for the Treatment of Helicobacter pylori Infection", Am. J. Gastercenterol. (1995) vol. 90, No. 1, pp. 60-63.
161 Kimura et al.; "A Case of Cerebrotendinous Xanthomatosis: Effects of Ursodeoxycholic Acid Administration on Serum Bile Acids and Cholestanol"; Jap J Med, vol. 21, No. 3; pp. 210-215, Jul. 1982.
162 Kirk et al.; "Inclusion Compounds"; Encyclopedia of Chemical Technology, Fourth Edition; vol. 14; pp. 125-135, 1995.
163 Knopp et al., "Long-Term Blood Cholesterol-Lowering Effects of a Dietary Fiber Supplement", Am J Pre. Med (1999) 17(1):18-23.
164 L. Dupuis et al.; "Evidence for Defective Energy Homeostasis in Amyotrophic Lateral Sclerosis: Benefit of a High-Energy Diet in a Transgenic Mouse Model"; www.pnas.org/cgi/doi/10.1073/pnas.0402026101 ; PNAS, Jul. 27, 2004, vol. 101, No. 30, pp. 11159-11164.
165 * Lee et al., "Regulation of Cyclin-Dependent Kinase 5 and p53 py ERK1/2 Pathway in the DNA Damage-Induced Neuronal Death" Journal of Cellular Physiology (2007) vol. 210 pp. 784-797.
166 Lehninger et al., "Carbohydrates and Glycobiology", Principles of Biochemistry, pp. 301-307, 2000.
167 Leuschner et al., "Oral Budesonide and Ursodeoxycholic Acid for Treatment of Primary Biliary Cirrhosis: Results of a Prospective Double-Blind Trial", Gastroenterology, (1999) vol. 117 pp. 918-925.
168 Lindor et al., "The Combination of Ursodeoxycholic Acid and Methotrexate for Patients with Primary Biliary Cirrhosis: The Results of a Pilot Study", Hepatology (1995) vol. 22, No. 4 pp. 1158-1162.
169 Lindor et al., "Ursodeoxycholic Acid in the Treatment of Primary Biliary Cirrhosis", Gastroenteral (1994) 106:1284-1290.
170 M. Föocking et al; "Statins Potentiate Caspase-3 Activity in Immortalized Murine Neurons"; Neuroscience Letters; vol. 355; pp. 41-44, 2003.
172 M.A. Vandelli et al.; "2-Hydroxypropy1-beta-Cyclodextrin Complexation With Ursodeoxycholic Acid"; International Journal of Pharmaceutics, vol. 118; pp. 77-83, 1995.
173 M.A. Vandelli et al.; "2-Hydroxypropy1-β-Cyclodextrin Complexation With Ursodeoxycholic Acid"; International Journal of Pharmaceutics, vol. 118; pp. 77-83, 1995.
174 M.G. Allwood et al.; "Stability of Ampicillin Infusions in Unbuffered and Buffered Saline"; International Journal of Pharmaceutics, vol. 97; pp. 219-224, 1993.
177 MacWalter et al.; "A Benefit-Risk Assessment of Agents Used in the Secondary Prevention of Stroke"; Drug Safety; vol. 25, No. 13; pp. 943-963, 2002.
178 Mathai et al., "The effect of bile acids on the growth and adherence of Helicobacter pylori", Aliment Pharmacol Therap. (1991) 5, pp. 653-668.
179 McLeod et al., "Glucocorticoid-Dextran Conjugates as Potential Prodrugs for Colon-Specific Delivery: Hydrolysis in Rat Gastrointestinal Tract Contents", J. Pharm Sci., (1994) vol. 83, No. 9., pp. 1284-1288.
180 McLeod et al., "Glucocorticoid-Dextran Conjugates as Potential Prodrugs for Colon-Specific Delivery: Steady-State Pharamacokinetics in the Rat", Biopharmaceutics & Drug Disposition, (1994) vol. 15, pp. 151-161.
181 McLeod et al., "Synthesis and Chemical Stability of Glucocoritcoid-Dextran Esters: Potential Prodrugs for Colon-Specific Delivery", International J. of Pharmaceutics, (1993) vol. 92 pp. 105-114.
182 Michael B. Jacobs; "HMG-CoA Reductase Inhibitor Therapy and Peripheral Neuropathy"; www.PubMed.com ; pp. 3, Jun. 1, 1994.
183 * Mishra et al., "Bleomycin-Mediated Pulmonary Toxicity: Evidence for a p53-Mediated Response" Am. J. Respir. Cell. Mol. Biol. (2000) vol. 22 pp. 543-549.
191 N. F.H. Ho, "Utilizing Bile Acid Carrier Mechanisms to Enhance Liver an Small Intestine Absorption", Annals New York Academy of Sciences, (1987) 507:315-29.
192 N. Shibata et al.; "Molecular Biological Approaches to Neurological Disorders Including Knockout and Transgenic Mouse Models"; Neuropathology, vol. 22; pp. 337-349, 2002.
194 Nagamatsu "Phase I Clinical Study of Ursodesoxycholic Acid" Jpn. Pharmacol. Ther. vol. 22, No. 6 (pp. 145-159) 1997.
196 Nishigaki, et al., "Ursodeoxycholic Acid Corrects Defective Natural Killer Activity by Inhibiting Prostaglandin E2 Production in Primary Biliary Cirrhosis", Digestive Diseases and Sciences, (1996) vol. 41, No. 7, pp. 1487-1493.
198 Oliva et al., "Ursodeoxycholate Alleviates Alcoholic Fatty Liver Damage in Rats", Alcohol Clin Exp Res., (1998), vol. 22, No. 7,pp. 1538-1543.
199 Osato et al., "Osmotic Effect of Honey on Growth and Viability of Helicobacter pylori", Digestive Diseases and Sciences, (1999) vol. 44, No. 3 pp. 462-464.
200 Ota et al.; "Metabolism of Bile Acids IV*. Absorption, Distribution, Excretion, and Metabolism of Orally Administered Ursodeoxycholic Acid in Rats"; Hiroshima Journal of Medical Sciences, vol. 26, No. 4; pp. 233-251, Dec. 1977.
201 P.J. Neveu, "The Effects of Thiol Moiety of Levamisole on Both Cellular and Humoral Immunity During the Early Response to a Hapten-Carrier Complex" Clin. Exp. Immunol. vol. 32, pp. 419-422, 1978.
202 P.J. Sinko, "Utility of Pharmacodynamic Measures for Assessing the Oral Bioavailability of Peptides. 1. Administration of Recombinant Salmon Calcitonin in Rats", Journal of Pharmaceutical Sciences, (1995) vol. 84, No. 11, pp. 1374-1378.
203 P.M. Preshaw et al., "Self-medication for the control of dental pain: what are our patients taking?", Dent Update vol. 21, pp. 299-301, 304, Sep. 1994.
204 P.P. But et al., "Ethnopharmacology of bear gall bladder: I" Journal of Ethnopharmacology vol. 47, pp. 27-31, 1995.
205 Panini et al., "The Influence of 2-Hydroxypropy1-β-Cyclodextrin on the Haemolysis Induced by Bile Acids", J. Pharm. Pharmacol., (1996) vol. 48 pp. 641-644.
206 Park et al.; "Cisplatin-Induced Apoptotic Cell Death in Mouse Hybrid Neurons Is Blocked by Antioxidants Through Suppression of Cisplatin-Mediated Accumulation of p53 but Not of Fas/Fas Ligand"; Journal of Neurochemistry, vol. 75, No. 3; pp. 946-953, 2000.
207 Parquet et al., "Bioavailability, Gastrointestinal Transit, Solubilization and Faecal Excretion of Ursodeoxycholic Acid in Man", European J. of Clinical Investigation, (1985) vol. 15 pp. 171-178. 1985.
208 Paumgartner et al., "Ursodeoxycholic Acid Treatment of Cholesterol Gallstone Disease", Scand J. Gastroenterol (1994) 29 Suppl 204: 28-31.
209 PCT International Search Report and Written Opinion, PCT/US2004/039507, 29 pages, Mailing Date Oct. 25, 2005.
210 PCT International Search Report PCT/US2004/039507 (12 pages), Mailing Date May 8, 2005.
211 PCT Notification of Transmittal of the International Search Report and Written Opinion PCT/US2006/008925, 10 pages, Mailing Date Jul. 21, 2006.
212 Podda et al., "Effect of Different Doses of Ursofeoxycholic Acid in Chronic Liver Disease", Digestive Diseases and Sciences, (1989) vol. 34, No. 12, Suppl. pp. 59S-65S.
213 Podda et al., "Gallstone Dissolution After 6 Months of Ursodeoxycholic Acid (UDCA): Effectiveness of Different Doses", J. Int. Med. Res., (1982) vol. 10 pp. 59-63.
214 Poupon, et al., "Ursodiol for the Long-Term Treatment of Primary Billary Cirrhosis", The New England Journal of Medicine, (1994) vol. 330, No. 19, pp. 1342-1347.
215 R. Panini et al.; "Improvement of Ursodeoxycholic Acid Bioavailability by 2-Hydroxypropyl-beta-Cyclodextrin Complexation in Healthy Volunteers"; Pharmacological Research; vol. 31, No. 314; pp. 205-209, 1995.
216 R. Panini et al.; "Improvement of Ursodeoxycholic Acid Bioavailability by 2-Hydroxypropyl-β-Cyclodextrin Complexation in Healthy Volunteers"; Pharmacological Research; vol. 31, No. 314; pp. 205-209, 1995.
217 R.E. Castro et al.; "The Bile Acid Tauroursodeoxycholic Acid Modulates Phosphorylation and Translocation of Bad via Phosphatidylinositol 3-Kinase in Glutamate-Induced Apoptosis of Rat Cortical Neurons"; American Society for Pharmacology and Experimental Therapeutics; pp. 34, Jun. 9, 2004.
218 R.L. Wynn, "New Reports on Dental Analgesics. NSAIDs and Cardiovascular Effects, Celecoxib for Dental Pain, and a New Analgesic-Tramadol With Acetaminophen" General Dentistry vol. 50, pp. 218-220, 222, May 2002.
219 R.L. Wynn, "New Reports on Dental Analgesics. NSAIDs and Cardiovascular Effects, Celecoxib for Dental Pain, and a New Analgesic—Tramadol With Acetaminophen" General Dentistry vol. 50, pp. 218-220, 222, May 2002.
220 R.L. Wynn, "Update on Nonprescription Pain Relievers for Dental Pain", General Dentistry vol. 52, pp. 94-98 ,Mar. 2004.
221 Remington: The Science and Practice of Pharmacy, Lippincott Williams and Wilkins, pp. 218, 2000.
222 Reynier et al. "Comparative Effects of Cholic, Chenodeoxycholic, and Ursodeoxycholic Acids on Micellar Solubilization and Intestinal Absorption of Cholesterol" J. of Lipid Research, vol. 22 (pp. 467-473), 1981.
223 Reynier et al., "Comparative Effects of Cholic, Chenodeoxycholic, and Ursodeoxycholic Acids on Micellar Solubilization and Intestinal Absorption of Cholesterol", J. Lipid Research, (1981) vol. 22 pp. 467-473. 1981.
224 Ribatti et al.; "Development of the Blood-Brain Barrier: A Historical Point of View"; The Anotomical Record (Part B: New Anat.); pp. 6, 2006.
225 Roda et al., "Improved Intestinal Absorption of an Enteric-Coated Sodium Ursodeoxycholate Formulation", Pharmaceutical Research, (1994) vol. 11, No. 5 pp. 642-647.
226 Roda et al., "Influence of Ursodeoxycholic Acid on Biliary Lipids", Scand J Gastroenterol (1994) 29 Suppl. 204:16-8.
227 Rodrigues et al. "Neuroprotection by a Bile Acid in an Acute Stroke Model in the Rat" Journal of Cerebral Blood Flow & Metabolism, vol. 22 (pp. 463-471), 2002.
228 Rodrigues et al., "The Site-Specific Delivery of Ursodeoxycholic Acid to the Rat Colon by Sulfate Conjugation", Gastroenterology (1995) vol. 109 pp. 1835-1844.
229 Rolandi et al., "Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis", Eur J. Clin Pharmacol (1991) 40:473-476.
230 S. Friman and J Svarik, "A Possible Role of Ursodeoxycholic Acid in Liver Transplantation", Scand J. Gastroenteral (1994) 29 Suppl. 204:62-4.
231 * Sauna et al., "Disulfram, an old drug with new potential therapeutic uses for human cancers and fungal infections" Mol. Biosyst. (2005) vol. 1, pp. 127-134.
232 * Scheithauer et al., "Direct effects of the hypoxic cell sensitizer misonidazole on colony formation in a human tumor cloning assay" Cancer Drug Delivery (1986) vol. 3 No. 1, abstract.
233 * Schuldes et al., "Reversal of multidrug resistance and increase in plasma membrane fluidity in CHO cells with R-verapamil and bile salts" European Journal of Cancer (2001) vol. 37 pp. 660-667.
234 Scott L. Myers et al., "Solid-State Emulsions: The Effects of Maltodextrin on Microcrystalline Aging", Pharmaceutical Research, (1993) vol. 10, No. 9 pp. 1389-1391.
235 Simoni et al., "Bioavailability Study of a New, Sinking, Enteric-Coated Ursodeoxycholic Acid Formulation", Pharmacological Research (1995) vol. 31, No. 2 pp. 115-119.
236 * Singhal et al., "Thalidomide in Cancer: Potential Uses and Limitations" BioDrugs (2001) vol. 15 No. 3, pp. 163-172.
237 Sinisalo et al., "Ursodeoxycholic Acid and Endothelial-Dependent, Nitric Oxide-Independent Vasodilatation of Forearm Resistance Arteries in Patients with Coronary Heart Disease", Br. J. Clin. Pharamcol., (1999) vol. 47 pp. 661-665.
238 Stefaniwsky et al., "Ursodeoxycholic Acid Treatment of Bile Reflux Gastritis", Gastroenterology (1985) vol. 89, pp. 1000-1004.
239 Strandvik et al., "Cystic Fibrosis: Is Treatment with Ursodeoxycholic Acid of Value?", Scand J Gastroenterol (1994) 29 Suppl. 204:65-7.
240 Sun Ah Park et al.; "Cisplatin-induced apoptotic cell death in mouse hybrid neurons is blocked by antioxidants through suppression of cisplatin-mediated accumulation of p53 but not of Fas/Fas ligand"; Journal of Neurochemistry, vol. 75, No. 3; pp. 946-953; ISSN: 0022-3042, 2000.
241 * Takeda et al., "Prevention of Irinotecan (CPT-11)-Induced Diarrhea by Oral Alkalization Combined With Control of Defecation in Cancer Patients" International Journal of Cancer (2001) vol. 92 pp. 269-275.
242 Tan et al., "Studies on Complexation between β-Cyclodextrin and Bile Salts", International J. Pharmaceutics, (1991) vol. 74 pp. 127-135.
243 Tanahashi et al., "Treatment of Acute Ischemic Stroke: Recent Progress" Internal Medicine vol. 41, pp. 337-344, 2002.
244 Tanaka et al., "Ligand-Independent Activiation of the Glucocorticord Receptor by Ursodeoxycholic Acid", The Journal of Immunology (1996) 156:1601-1608, 1996.
245 * The American Heritage Dictionary, Second College Edition, published 1982 by Houghton Mifflin Company, p. 1213.
246 Thorsteinn Loftsson et al., "The Effect of Cyclodextrins on the Solubility and Stability of Medroxyprogesterone Acetate and Megestrol Acetate in Aqueous Solution", International J. of Pharmaceutics, (1993) vol. 98 pp. 225-230.
247 U. Leuschner et al., "Ursodeoxycholic Acid Therapy in Primary Biliary Cirrhosis", Scand J. Gastroenteral (1994) 29 Suppl. 204:40-6.
248 V. Fontes et al., "Recurrent Aphthous Stomatitis: Treatment With Colchicine. An Open Trial of 54 Cases", Ann. Dermatol. Venereol. vol. 129, pp. 1365-1369 , (with abstract) 2002.
249 V.S. Kasture et al.,"Anticonvulsant activity of Albizzia lebbeck leaves" Indian Journal of Experimental Biology vol. 34, pp. 78-80, Jan. 1996.
250 V.S. Kasture et al.,"Anticonvulsive activity of Albizzia lebbeck, Hibiscus rosa sinesis and Butea monosperma in experimental animals" Journal of Ethnopharmacology vol. 71, pp. 65-75, 2000.
251 Van Caekenberghe et al., "In Vitro Synergistic Activity between Bismuth Subcitrate and Various Antimicrobial Agents against Campylobacter pylorids", Antimicrobial Agent and Chemotherapy, (1987) vol. 31, No. 9, pp. 1429-1430.
252 Verrips et al. "Effect of Simvastatin in Addition to Chenodeoxycholic Acid in Patients with Cerebrotendinous Xanthomatosis" Metabolism, vol. 48, No. 2 (pp. 233-238), Feb. 1999.
253 Villaneuva et al. "Effect of Bile Acids of Hepatobiliary Transport of Cisplatin by Perfused Rat Liver" Pharmacology and Toxicology, vol. 80, No. 3 (pp. 111-117), Sep. 29, 1996.
254 Wacker Biochem. Corp., advertisement, C&EN, 31 (Apr. 12, 1999).
255 Walker et al., "Intestinal Absorpotion of Ursodeoxycholic Acid in Patients With Extrahepatic Biliary Obstruction and Bile Drainage", Gastroenterology (1992) 102:810-815.
256 Wardlaw et al.; "Thrombolysis for Acute Ischaemic Stroke"; Cochrane Database of Systematic Views; Issue 3; pp. 98, 2003.
257 * Williams et al., "The Proteasome Inhibitor Bortezomib Stabilizes a Novel Active Form of p53 in Human LNCaP-Pro5 Prostate Cancer Cells" Cancer Research (2003) vol. 63 pp. 7338-7344.
258 XP 002337363, May 10, 1998, XP (abstract).
259 XP 002337364, Oct. 7, 1988, XP (abstract).
260 XP 002337365, Jul. 8, 1987, XP (abstract).
261 XP 002337367, Feb. 1, 1994, XP (abstract).
262 Y. Hattori, et al.; "Ursodeoxycholic Acid Inhibits the Induction of Nitric Oxide Synthase"; European Journal of Pharmacology; pp. 147-150, 1996.
263 * Yamaguchi et al., "Regulation of Bax Activation and Apoptotic Response to Microtubule-damaging Agents by p53 Transcription-dependent and -independent Pathways" Journal of Biological Chemistry (2004) vol. 279 No. 38, pp. 39431-39437.
264 * Youlyouz et al., "Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents" Cell Death and Differentiation (2008) vol. 15 pp. 376-385.
265 Zentler-Munro et al., "Effect of Intrajejunal Acidity on Aqueous Phase Bile Acid and Lipid Concentrations in Pancreatic Steatorrhoea Due to Cystic Fibrosis", Gut (1984) vol. 25 pp. 500-507.
266 Ziv et al., "Bile Salts Facilitate the Absorption of Heparin from the Intestine", Biochemical Pharmacology, (1983) vol. 32, No. 5 pp. 773-776.
US9511045 * Mar 2, 2011 Dec 6, 2016 Universite D'auvergne Clermont I Use of riluzole for treating or preventing the adverse effects of antineoplastic agents
US20130064775 * Mar 2, 2011 Mar 14, 2013 Universite D'auvergne Clermont I Use of riluzole for treating or preventing the adverse effects of antineoplastic agents
CN102178685A * Mar 3, 2011 Sep 14, 2011 山东农业大学 Application of taurochenodeoxycholic acid in protection of adrenal gland function
CN102178685B Mar 3, 2011 Dec 5, 2012 山东农业大学 Application of taurochenodeoxycholic acid in protection of adrenal gland function
U.S. Classification 514/171, 514/182, 552/550, 552/549
International Classification C07J9/00, A61K31/575, C07J41/00
Cooperative Classification A61K47/554, A61K31/715, A61K45/06, A61K31/575, A61K9/0095, A61K35/413, A61K31/718
European Classification A61K31/575, A61K31/715, A61K31/718, A61K35/413, A61K47/48H4R, A61K9/00Z6, A61K45/06